Catalyst Pharmaceuticals stock leaves Nasdaq after USD 4.1 billion deal

Catalyst Pharmaceuticals stock was converted into USD 31.50 in cash per share when Angelini Pharma completed its acquisition of the company on July 16, 2026. The transaction assigned Catalyst an equity value of USD 4.1 billion and ended its trading on the Nasdaq Global Market.

USD 31.50 merger consideration

According to GlobeNewswire, each outstanding Catalyst common share was canceled and converted into the right to receive USD 31.50 in cash without interest. The merger therefore set a defined cash value rather than leaving shareholders exposed to further public-market price changes.

The deal value was USD 4.1 billion on an equity basis, while the per-share consideration was USD 31.50. That comparison puts the transaction in a different category from a routine licensing agreement and explains why the company moved from a listed stock to private ownership.

Rare disease portfolio remains central

Catalyst's investor relations site describes the company as a biopharmaceutical group focused on rare and difficult-to-treat conditions. Its commercial work has centered on marketed therapies and patient support programs, while the business has emphasized expanding treatment options in rare disease.

The company site also states that Catalyst ranked number 11 on Forbes' 2026 list of America's Most Successful Small-Cap Companies. That recognition provides operating context for the acquisition, but the decisive investor event was the completed merger and its USD 31.50 cash consideration.

Nasdaq trading status changes

The transaction changed the status of CPRX from a Nasdaq-listed security to an acquired company whose common stock ceased trading on the Nasdaq Global Market. For former shareholders, the key reference is the July 16, 2026 closing date and the USD 31.50 per-share cash entitlement.

More company news and analyses on Catalyst Pharmaceuticals stock